Protopic Study Attempts To Show Similar Burning, Better Efficacy Than Elidel
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Fujisawa is addressing the perception that Protopic has a higher rate of application site burning than Novartis’ Elidel with data suggesting a similar incidence in patients with mild atopic dermatitis.